<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01403090</url>
  </required_header>
  <id_info>
    <org_study_id>CPR-001</org_study_id>
    <nct_id>NCT01403090</nct_id>
  </id_info>
  <brief_title>Safety Study of the Angel™ Catheter in Subjects With Risk of Pulmonary Embolism</brief_title>
  <official_title>A Single Treatment, Open Label, Multicenter, Safety Study of the Angel™ Catheter in Hospitalized Human Subjects With a Temporary Risk of Pulmonary Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BiO2 Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BiO2 Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Angel™ Catheter combines the functions of a vena cava filter and a multi-lumen central
      line catheter. The device is designed to be placed in the inferior vena cava via the femoral
      vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous
      system. The primary endpoint is freedom from serious adverse events (SAE), defined as death,
      symptomatic pulmonary embolism or major bleeding .
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>30 days</time_frame>
    <description>Device safety was evaluated on the basis of identification and summarization of the incidence rates of complications and adverse effects.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Pulmonary Embolism</condition>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Angel Catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Angel Catheter</intervention_name>
    <description>The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.</description>
    <arm_group_label>Angel Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is 18 years and older

          2. Be admitted to the hospital

             One of the following two criteria:

          3. Patients with proven deep vein thrombosis (DVT) or pulmonary embolism ( PE), at high
             risk for pulmonary embolism and under consideration for insertion of a retrievable
             inferior vena cava (IVC) filter with at least one of the following criteria:

               -  Contraindications for anticoagulation

               -  Recurrent PE despite adequate anticoagulation

               -  Emergency treatment following massive pulmonary embolism

          4. Patients at high risk for developing PE who require but have a temporary or absolute
             contraindication for prophylaxis with anticoagulation, including:

               -  Patients with multiple trauma and active or recent bleeding with
                  contraindications to anticoagulation or that require a temporary stop of
                  anticoagulation

               -  severe head injury with coma

               -  severe hemorrhagic stroke with coma

               -  head injury with a long bone fracture

               -  spinal cord injury with paraplegia or quadriplegia

               -  multiple (≥2) long bone fractures with pelvic fracture

               -  multiple (≥4) long bone fractures

               -  Critically ill patients in the Medical or Surgical Intensive Care Unit with high
                  risk of PE that require but are contraindicated for anticoagulation prophylaxis
                  and will benefit from a temporary filter and a central venous access catheter

               -  Patients who had recently undergone or are about to undergo a surgical procedure
                  that requires temporary interruption of anticoagulation for Venous
                  Thromboembolism (VTE) and will benefit from a temporary vena cava filter and
                  central

        Exclusion Criteria:

          1. Patient is less than 18 years

          2. Patient is pregnant or has a positive serum human chorionic gonadotropin (HCG)
             pregnancy test at baseline visit

          3. Patient or next legal representative cannot give informed consent

          4. Patients with anticipated survival &lt; 2 days (catastrophic illness)

          5. Body mass index greater than 35

          6. Patient has a pre-existing filter

          7. Participation in another simultaneous interventional medical investigation or
             interventional trial.

          8. Patient has indications for a permanent filter at the time of the initial evaluation

          9. Patient has an uncontrollable coagulopathy with active bleeding.

         10. Patient with proven endocarditis or bacteremia

         11. Patient has hypersensitivity to any of the components of the Angel™ Catheter,
             specifically Nitinol

         12. Known acute or chronic thrombotic occlusion of both common femoral veins or iliac
             veins

         13. Patient with functioning pelvic renal allograft on the only side available for device
             insertion

         14. Patient who will undergo surgical procedure involving the femoral vein or pelvic veins
             through which the device must be inserted
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Cadavid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Pablo Tobon Uribe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bladimir Gil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Las Americas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinica las Americas</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2011</study_first_submitted>
  <study_first_submitted_qc>July 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2011</study_first_posted>
  <results_first_submitted>August 15, 2012</results_first_submitted>
  <results_first_submitted_qc>April 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 20, 2013</results_first_posted>
  <last_update_submitted>April 10, 2013</last_update_submitted>
  <last_update_submitted_qc>April 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Embolism</keyword>
  <keyword>Deep Vein Thrombosis</keyword>
  <keyword>Venous Thromboembolism</keyword>
  <keyword>Central Line Catheter</keyword>
  <keyword>Vena Cava Filters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment started at the Hospital Pablo Tobon Uribe and was then followed at the clinical las Americas. Eight patients were recruited in the initial phase of the study</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Angel Catheter</title>
          <description>Angel Catheter Placement : The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Angel Catheter</title>
          <description>Angel Catheter Placement : The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.4" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety</title>
        <description>Device safety was evaluated on the basis of identification and summarization of the incidence rates of complications and adverse effects.</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Angel Catheter</title>
            <description>Angel Catheter Placement : The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety</title>
          <description>Device safety was evaluated on the basis of identification and summarization of the incidence rates of complications and adverse effects.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Angel Catheter</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Luis Angel, MD</name_or_title>
      <organization>BiO2 medical</organization>
      <phone>2102139778</phone>
      <email>langel@bio2medical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

